The company also plans to broaden its product pipeline and focus on niche technologies in peptides, oncology drugs, hormonal products and nutraceuticals as well. The company's consolidated revenue from operations stood at R8,100 crore in FY14 as against R5,855 crore in the previous year, up by 38.3%.
Aurobindo is making headway in drug development of anti-cancer drugs and hormonal products, both in solid and parenteral dosage forms. In 2014-15, filings for approvals are being planned for a few products. While continuing to develop formulations in various therapeutic and dosage form areas, R&D efforts are also directed at exploring innovative products and platform technologies.
Besides, the company hopes to seek approvals for nine more injectables from the USFDA. "In the injectable business, going forward, we are gearing ourselves for a meaningful growth in the medium term. We have 45 files with FDA under review, and we hope to file 9 more in 2014-15 and another 30 in 2015-16. Hence, depending on the timing of the regulatory approvals, we could see significant growth over the next two to three years," it said. The company said it has achieved a remarkable milestone of 300 submissions to the USFDA at the end of 2013 and as at end of March 2014 the submissions totaled 336 ANDA filings.